Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese Updated Monday, February 20, 2017
Submit a manuscript
Send response
Read responses
Advance online publication
Sign up for e-alert
JCIM job opportunities
Contact JCIM
 Information For
 About JCIM
Journal description
Editorial policy
Privacy policy
Copy right
Editorial staff
 Language Polishing
Journal of Chinese Integrative Medicine: 2011; 9(5): 495-502
DOI: 10.3736/jcim20110506
Treatment effects of traditional Chinese medicines Suoquan Pill and Wuling Powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebo-controlled trial
1. Chia-Chun Hung (Psychiatry Department, Taichung Veterans General Hospital, Taichung, Taiwan, China )
2. Pin-Kuei Fu (Psychiatry Department, Taichung Veterans General Hospital, Taichung, Taiwan, China )
3. Hsyn-Yi Wang (Nuclear Medicine Department, Taichung Veterans General Hospital, Taichung, Taiwan, China )
4. Chin-Hong Chan (Psychiatry Department, Taichung Veterans General Hospital, Taichung, Taiwan, China )
5. Tsuo-Hung Lan (Psychiatry Department, Taichung Veterans General Hospital, Taichung, Taiwan, China E-mail: thlan@ym.edu.tw, tosafish@gmail.com)

Background: It is reported that 30% to 80% schizophrenia patients suffered from hypersalivation when taking clozapine. Some investigations of the use of formulas of traditional Chinese medicine (TCM) to treat clozapine-induced hypersalivation suggested their potential treatment effects. In these formulas, Suoquan Pill (SQP) and Wuling Powder (WLP) were suggested to have therapeutic effects in improving clozapine-induced hypersalivation.
Methods and design: A prospective, double-blind, randomized, placebo-controlled study will be conducted to test the therapeutic effects of SQP and WLP in relieving hypersalivation in patients taking clozapine. A total of 45 patients will be enrolled into this study with 15 in each treatment group. Patients will receive medication according to their assigned group. Either SQP 10 g per oral dose twice daily, WLP 10 g per oral dose twice daily or placebo powder 10 g per oral dose twice daily will be prescribed to the patients for 8 weeks. The Drooling Severity Scale, Nocturnal Hypersalivation Rating Scale and sialoscintigraphy will be used as the primary outcome measures; the Clinical Global Impressions Severity, the Positive and Negative Syndrome Scale, the Abnormal Involuntary Movement Scale, the Simpson-Angus Scale and the TCM constitutional scale will be used as the secondary outcome measures
Discussion: It is hypothesized that SQP and WLP will have a beneficial effect in controlling clozapine-induced hypersalivation symptoms. It may also improve the life quality of psychotic patients by improving their mental status.
Trial registration: ClinicalTrials.gov (Identifier: NCT01045720).

Welcome to JCIM! You are the number 19506 reader of this article!
Download Article:
[Full Text]      [PDF]      [Chinese]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Hung CC, Fu PK, Wang HY, Chan CH, Lan TH. Treatment effects of traditional Chinese medicines Suoquan Pill and Wuling Powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebo-controlled trial. J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. 2011; 9(5): 495-502.
1Miller DD. Review and management of clozapine side effects[J].J Clin Psychiatry, 2000, 61(Suppl 8): 14-17;discussion 18-19.  .
2Cree A, Mir S, Fahy T. A review of the treatment options for clozapine-induced hypersalivation[J].Psychiatr Bull, 2001, 25(3): 114-116.  .
3Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies[J].Psychopharmacology (Berl), 2006, 185(3): 265-273.  .
4Rogers DP, Shramko JK. Therapeutic options in the treatment of clozapine-induced sialorrhea[J].Pharmacotherapy, 2000, 20(9): 1092-1095.  .
5Freudenreich O, Beebe M, Goff DC. Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series[J].J Clin Psychopharmacol, 2004, 24(1): 98-100.  .
6Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE, Mohan S. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine[J].Clin Drug Investig, 1999, 17(2): 97-102.  .
7Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis[J].Psychiatr Q, 1992, 63(1): 51-70.  .
8Safferman A, Liberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine[J].Schizophr Bull, 1991, 17(2): 247-261.  .
9Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease[J].J Clin Gastroenterol, 2005, 39(2): 89-97.  .
10Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine[J].Am J Psychiatry, 1995, 152(2): 297-298.  .
11Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling[J].Am J Psychiatry, 1996, 153(3): 445.  .
12Drug-induced sialorrhoea and excessive saliva accumulation[J].Prescrire Int, 2009, 18(101): 119-121.  .
13Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M. Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea[J].J Clin Psychopharmacol, 1996, 16(6): 462-463.  .
14Pearlman C. Clozapine, nocturnal sialorrhea, and choking[J].J Clin Psychopharmacol, 1994, 14(4): 283.  .
15Berlan M, Montastruc JL, Lafontan M. Pharmacological prospects for α2-adrenoceptor antagonist therapy[J].Trends Pharmacol Sci, 1992, 13(7): 277-282.  .
16Mandel ID, Zengo A, Katz R, Wotman S. Effect of adrenergic agents on salivary composition[J].J Dent Res, 1975, 54(Spec No B): B27-B33.  .
17Davydov L, Botts SR. Clozapine-induced hypersalivation[J].Ann Pharmacother, 2000, 34(5): 662-665.  .
18Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist[J].Eur J Pharmacol, 1994, 269(3): R1-R2.  .
19Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study[J].Biol Psychiatry, 1996, 40(11): 1132-1134.  .
20Grabowski J. Clonidine treatment of clozapine-induced hypersalivation[J].J Clin Psychopharmacol, 1992, 12(1): 69-70.  .
21Praharaj SK, Verma P, Roy D, Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea?[J].J Psychopharmacol, 2005, 19(4): 426-428.  .
22Corrigan FM, MacDonald S, Reynolds GP. Clozapine-induced hypersalivation and the alpha 2 adrenoceptor[J].Br J Psychiatry, 1995, 167(3): 412.  .
23Webber MA, Szwast SJ, Steadman TM, Frazer A, Malloy FW, Lightfoot JD, Shekhar A. Guanfacine treatment of clozapine-induced sialorrhea[J].J Clin Psychopharmacol, 2004, 24(6): 675-676.  .
24Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study[J].J Clin Psychopharmacol, 2001, 21(6): 608-611.  .
25Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation[J].Lancet, 1995, 346(8981): 1034.  .
26Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe[J].Pharmacopsychiatry, 2004, 37(2): 43-45.  .
27Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect[J].J Psychiatry Neurosci, 1999, 24(3): 250.  .
28Comley C, Galletly C, Ash D. Use of atropine eye drops for clozapine induced hypersalivation[J].Aust N Z J Psychiatry, 2000, 34(6): 1033-1034.  .
29Sharma A, Ramaswamy S, Dahl E, Dewan V. Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea[J].Ann Pharmacother, 2004, 38(9): 1538.  .
30Aggarwal A, Garg A, Jiloha RC. Trihexyphenidyl (benzhexol) in clozapine-induced nocturnal enuresis and sialorrhea[J].Indian J Med Sci, 2009, 63(10): 470-471.  .
31Poyurovsky M, Modai I, Weizman A. Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis[J].Int Clin Psychopharmacol, 1996, 11(1): 61-63.  .
32Praharaj SK, Sarkhel S, Khanande RV, Sinha VK. Complete resolution of clozapine-induced sialorrhea with low dose trihexyphenidyl[J].Psychopharmacol Bull, 2010, 43(4): 73-75.  .
33Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A. Trihexyphenidyl treatment of clozapine-induced hypersalivation[J].Int Clin Psychopharmacol, 1997, 12(4): 213-215.  .
34Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating from clozapine[J].Am J Psychiatry, 2001, 158(8): 1329-1330.  .
35Calderon J, Rubin E, Sobota WL. Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report[J].Int Clin Psychopharmacol, 2000, 15(1): 49-52.  .
36Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study[J].J Clin Psychiatry, 2009, 70(8): 1114-1119.  .
37Duggal HS. Glycopyrrolate for clozapine-induced sialorrhea[J].Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31(7): 1546-1547.  .
38Liang CS, Ho PS, Shen LJ, Lee WK, Yang FW, Chiang KT. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study[J].Schizophr Res, 2010, 119(1-3): 138-144.  .
39Robb AS, Lee RH, Cooper EB, Siedel JV, Nusrat N. Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents[J].J Child Adolesc Psychopharmacol, 2008, 18(1): 99-107.  .
40Gaftanyuk O, Trestman RL. Scolpolamine patch for clozapine-induced sialorrhea[J].Psychiatr Serv, 2004, 55(3): 318.  .
41Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation - a case report[J].Pharmacopsychiatry, 2005, 38(1): 38-39.  .
42Kreinin A, Epshtein S, Sheinkman A, Tell E. Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study[J].Isr J Psychiatry Relat Sci, 2005, 42(1): 61-63.  .
43Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study[J].Int Clin Psychopharmacol, 2006, 21(2): 99-103.  .
44Praharaj SK, Ray P, Gandotra S. Amisulpride improved debilitating clozapine-induced sialorrhea[J].Am J Ther, 2010, : Epub ahead of print.  .
45Praharaj SK, Sarkar S, Sinha VK. Amisulpride treatment for clozapine-induced sialorrhea[J].J Clin Psychopharmacol, 2009, 29(2): 189-190.  .
46Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced sialorrhoea[J].Br J Psychiatry, 1991, 159: 166.  .
47Kreinin A, Miodownik C, Libov I, Shestakova D, Lerner V. Moclobemide treatment of clozapine-induced hypersalivation: pilot open study[J].Clin Neuropharmacol, 2009, 32(3): 151-153.  .
48Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea[J].Br J Clin Pharmacol, 2007, 63(1): 128-129.  .
49Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for clozapine-induced hypersalivation[J].Cochrane Database Syst Rev, 2008, (3): CD005579.  .
50Kahl KG, Hagenah J, Zapf S, Trillenberg P, Klein C, Lencer R. Botulinum toxin as an effective treatment of clozapine-induced hypersalivation[J].Psychopharmacology (Berl), 2004, 173(1-2): 229-230.  .
51Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea[J].Psychopharmacology (Berl), 2010, 207(4): 593-597.  .
52Conry A, Siris SG, Bermanzohn PC. Improvement of clozapine-induced sialorrhea after septoplasty[J].Am J Psychiatry, 1996, 153(3): 444.  .
53Sockalingam S, Remington G. Review: insufficient evidence to guide use of drugs for clozapine induced hypersalivation[J].Evid Based Ment Health, 2009, 12(1): 12.  .
54Syed Sheriff RJ, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for clozapine-induced hypersalivation[J].Schizophr Bull, 2008, 34(4): 611-612.  .
55Kang B, Liu YC, Zhang YP, Han Y, Fan LZ, Zhou J. Effects of Suoquan Pill for reducing clozapine-induced salivation[J].Zhongguo Zhong Xi Yi Jie He Za Zhi, 1993, 13(6): 347-348. Chinese.
56American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-Ⅳ-TR). Text revision. 4th ed. Washington DC: American Psychiatric Association. 2000
57Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy[J].Laryngoscope, 2002, 112(1): 73-81.  .
58Jongerius PH, van Limbeek J, Rotteveel JJ. Assessment of salivary flow rate: biologic variation and measure error[J].Laryngoscope, 2004, 114(10): 1801-1804.  .
59Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC. Salivary gland 99mTc-scintigraphy: a grading scale and correlation with major salivary gland flow rates[J].J Oral Pathol Med, 1992, 21(2): 70-74.  .
60Umehara I, Yamada I, Murata Y, Takahashi Y, Okada N, Shibuya H. Quantitative evaluation of salivary gland scintigraphy in Sjorgen's syndrome[J].J Nucl Med, 1999, 40(1): 64-69.  .
61Vigh L, Carlsen O, Hartling OJ. Uptake index and stimulated salivary gland response in 99Tcm-pertechnetate salivary gland scintigraphy in normal subjects[J].Nucl Med Commun, 1997, 18(4): 363-366.  .
62Bohuslavizki KH, Brenner W, Tinnemeyer S, Wolf H, Sippel C, Tonshoff G, Karde P, Stauch C, Clausen M, Henze E. Normal data base for quantitative salivary gland scintigraphy[J].Radiol Oncol, 1995, 29(4): 297-305.  .
63Guy W, National Institute of Mental Health (U.S.), Psychopharmacology Research Branch; Early Clinical Drug Evaluation Program. ECDEU assessment manual for psychopharmacology. Revised ed. Rockville: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs. 1976.
64Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia[J].Schizophr Bull, 1987, 13(2): 261-276.  .
65Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale[J].Hosp Community Psychiatry, 1988, 39(11): 1172-1177.  .
66Simpson GM, Angus JW. A rating scale for extrapyramidal side effects[J].Acta Psychiatr Scand Suppl, 1970, 212: 11-19.  .
67China Association of Chinese Medicine. ZYYXH/T157-2009 Classification and determination of constitution in TCM[M]. Beijing: China Press of Traditional Chinese Medicine, 2009. Chinese.
68World Health Organization. WHO launches the first global strategy on traditional and alternative medicine.
69Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients[J].Br J Psychiatry Suppl, 1992, (17): 30-33.  .
70Farde L, Nordstrom AL, Nyberg S, Halldin C, Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients[J].J Clin Psychiatry, 1994, 55(Suppl B): 67-69.  .
71Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects[J].Arch Gen Psychiatry, 1992, 49(7): 538-544.  .
72Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials[J].Am J Psychiatry, 2001, 158(4): 518-526.  .
73Solanki RK, Singh P, Swami MK. Clozapine: current perspective[J].Indian J Psychiatry, 2007, 49(4): 271-276.  .
74Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics[J].J Psychopharmacol, 2000, 14(4): 409-418.  .
75Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials[J].Schizophr Res, 2002, 56(1-2): 1-10.  .
76Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials[J].Am J Psychiatry, 1999, 156(7): 990-999.  .
77Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY. Clozapine for treatment-refractory mania[J].Am J Psychiatry, 1996, 156(6): 759-764.  .
78Ciapparelli A, Dell’Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study[J].J Clin Psychiatry, 2003, 64(4): 451-458.  .
79Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients[J].Eur Arch Psychiatry Clin Neurosci, 2005, 255(1): 10-14.  .
80Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment-refractory mood disorders[J].J Clin Psychiatry, 1994, 55(Suppl B): 91-93.  .
81Mahmood T, Devlin M, Silverstone T. Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment[J].Aust N Z J Psychiatry, 1997, 31(3): 424-426.  .
82McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O’Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia[J].J Clin Psychiatry, 1991, 52(10): 411-414.  .
83Tiihonen J, Lnnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)[J].Lancet, 2009, 374(9690): 620-627.  .
84Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine[J].Adv Neurol, 1993, 60: 703-706.  .
85Rosenthal SH, Fenton ML, Harnett DS. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease[J].Gen Hosp Psychiatry, 1992, 14(4): 285-286.  .
86Kane JM, Honigfeld G, Singer J, Meltzer H, the Clozapine Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial[J].Psychopharmacology (Berl), 1989, 99(Suppl 1): S60-S63.  .

 Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese
Copyright © 2003-2012 by JCIM Press. All rights reserved. ISSN 1672-1977